Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.

Luigi D'Antonio,Cristiano Fieni,Stefania Livia Ciummo,Simone Vespa,Lavinia Lotti,Carlo Sorrentino,Emma Di Carlo

Journal for immunotherapy of cancer（2023）

引用 3|浏览7

暂无评分

摘要

IL30 is a new CRC driver, since its inactivation, which disables oncogenic pathways and multiple autocrine loops, inhibits CR-CSC tumorigenicity and metastatic ability. The development of CRISPR/Cas9-mediated targeting of IL30 could improve the current therapeutic landscape of CRC.

查看译文

关键词

cytokines,gastrointestinal neoplasms

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要